QMS Medical Allied Services: Services Mix Shifts Up as Q1 FY27 Starts Strong

QMS Medical Allied Services opened FY27 with a quarter that highlighted an important change in its business mix. Consolidated revenue from operations rose to INR 56.9 crore in Q1 FY27, up 22% year on year. Profitability also improved faster than revenue. EBITDA increased 27% to INR 8.3 crore, and the EBITDA margin expanded to 14.6% from 14.1% in Q1 FY26. PAT stood at INR 4.0 crore, up 25% year on year, with PAT margin at 7.0%.

Management attributed the improved operating performance to investments made in FY26 across people, technology, infrastructure, and service capabilities. The quarter also comes soon after the company’s migration to the NSE Main Board on June 18, 2026, which management positioned as a milestone in building a larger and more diversified healthcare services platform.

The key shift: services are becoming a larger part of revenue

The clearest signal in the quarter was the change in segment mix. In Q1 FY27, products contributed 59% of consolidated revenue while services contributed 41%. In Q1 FY26, the mix was 76% products and 24% services. Management stated that this rising share of services is also a driver of gross margin expansion, while product margins are broadly stable.

Within the products business, the company operates through multiple channels, including pharma companies and hospitals, point-of-care sales linked to camps and clinics, and e-commerce. The investor presentation states that QMS clocked INR 33 crore of product revenue in Q1 FY27 (including Q-Devices). It also provides channel revenue points within products: pharma companies and hospitals at INR 24 crore, point-of-care at INR 9 crore, and e-commerce at INR 0.16 crore.

On the services side, the portfolio is centered around Patient Support Programs (PSPs) and B2B health camps. Management stated that PSP revenue including Saarathi Healthcare was about INR 17.6 crore in Q1 FY27. Camp revenue for Q1 FY27 was stated at INR 6.4 crore in the presentation.

A notable disclosure during the earnings call was a correction to a misprinted figure. The finance team clarified that B2B camps revenue for Q1 FY27 was INR 6.4 crore and not INR 13.68 crore, and indicated a revised file would be uploaded.

Services execution at scale: camps and PSPs as complementary levers

QMS positions its services offering as a patient journey model that connects pharma companies, doctors, and end beneficiaries. The investor presentation describes service delivery elements such as disease management, diet and lifestyle counselling, diagnostics, screening camps, digital engagement, and reporting and analytics through dashboards.

Operationally, the company highlights a central tele-counselling centre supported by CRM, and on-ground field support involving physios, nutritionists, nurses, and field teams for camps. Management stated it conducted 11,497 B2B health camps in Q1 FY27, and the presentation shows camps scaling from 24,823 in FY24 to 32,380 in FY26.

Management also presented a strategic linkage between camps and PSPs. Camps are positioned as an entry point for screening and early diagnosis, while PSPs are designed for longer-term engagement such as therapy initiation, counselling, adherence tracking, and follow-ups.

The earnings call also discussed the cost structure of PSPs. The finance team stated that PSP contracts are typically cost-plus with a markup, with some programs requiring payroll hiring rather than contractual staffing. Management indicated employee cost should be largely stable, with potential increase if new projects are added or existing projects scale up.

Products strategy: own-brand Q-Devices and point-of-care expansion

Within products, the company is leaning into Q-Devices, its own brand launched in 2023. In the call, management stated Q-Devices revenue was approximately INR 3 crore in Q1 FY27, and INR 14 crore in FY26. Management also stated it is targeting 10% to 15% contribution from Q-Devices, and in about three years, 20% to 25% of total product revenue from Q-Devices.

The presentation lists examples in the Q-Devices portfolio, including braces, nebulizers, heating pads, and an automatic blood pressure monitor. Management also mentioned adding point-of-care products into a new portfolio and indicated that these are expected to be put into the market by around Q3.

The company also highlights distribution reach as an entry barrier. It cites 900+ SKUs, 5,000+ serviceable pin codes, and a pan-India network across 100+ cities. It also states it is a government-approved vendor on the eGrameen portal, and the roadmap slide positions eGrameen access as a lever to expand into underserved rural and semi-urban markets.

Saarathi consolidation and what it means for the services platform

A key corporate development remains Saarathi Healthcare, where QMS holds a 76% stake. Management stated it expects to acquire the balance stake by end of Q2 FY27. The rationale, as stated, is to strengthen disease management and PSP capabilities and address the full patient journey more comprehensively.

However, when asked about Saarathi’s separate profitability profile, the finance team did not provide a split and stated that service contracts are divided between QMS and Saarathi depending on relationships, capability, and registrations. As a result, the documents do not provide enough data to independently validate Saarathi’s standalone profitability contribution.

Takeaways from the quarter

Q1 FY27 shows QMS continuing to scale its integrated model, with services moving from a supporting role to a material contributor. The reported mix shift towards services is a clear driver behind improving consolidated margins, and management continues to position camps and PSPs as a combined operating engine.

The quarter also had a disclosure reminder. The company informed the exchange that slides 19 and 20 in the investor presentation had typographical errors that were rectified, and the earnings call explicitly corrected a misprinted B2B camps revenue number.

Management maintained its stance on full-year guidance during the call, stating it was too early in the year to revise assumptions, even though Q1 started strong. For investors tracking execution, the next few quarters will likely center on three verifiable markers discussed by management: completion of the Saarathi balance acquisition by end of Q2, sustained services momentum through PSP renewals and new wins, and the planned point-of-care portfolio push around Q3.